T Cell News and Research

Latest T Cell News and Research

D614G mutation enhances stability of SARS-CoV-2 spike protein

A new study, published on the preprint server bioRxiv in November 2020 by researchers at the Indian Institute of Science, has explored this issue further. The researchers have found that this mutation is associated with structural and energetic changes that cause this spike variant to become more available during infection, thus rendering the associated strain more infective.

4 Nov 2020

RNA-binding proteins may suppress antiviral defenses against SARS-CoV-2

Conducted by researchers in South Korea at the Institute for Basic Science and the International Vaccine Institute, a new study published on the preprint server bioRxiv in November 2020 describes the many host proteins that bind with the ribonucleic acid (RNA) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and regulate the replication of the virus.

4 Nov 2020

Study shows brilacidin strongly inhibits SARS-CoV-2 in laboratory cell lines

A recent study by US researchers reveals that brilacidin, a small synthetic molecule with peptide-like properties, exerts potent in vitro antiviral activity against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – both as a standalone treatment and in combination with FDA-approved remdesivir. The study is currently available on the bioRxiv preprint server.

4 Nov 2020

Researchers develop novel therapeutic approach against COPD

Chronic obstructive pulmonary disease (COPD) is one of the most common and deadliest diseases worldwide.

4 Nov 2020

Chikungunya can infect central nervous system and impair cognitive, motor functions

A study conducted by an international team of researchers with FAPESP's support shows that infection by chikungunya virus can produce even more severe manifestations than the typical symptoms of the disease, such as acute fever, headache, rash, and intense joint and muscle pain.

4 Nov 2020

Genetic mutation may accelerate heart function decline in DMD patients

A mutation in the gene that causes cystic fibrosis may accelerate heart function decline in those with Duchenne muscular dystrophy (DMD), a new study by UT Southwestern researchers suggests.

4 Nov 2020

Synthetic antibody may prevent coronavirus from infecting human cells

By screening hundreds of synthetic antibodies, researchers at Karolinska Institutet in Sweden and EMBL Hamburg in Germany have identified an antibody that may prevent the new coronavirus from infecting human cells.

4 Nov 2020

REGENHU launches its next generation 3D Bioprinter and software, the R-GEN series and SHAPER, in its mission to revolutionize medicine

REGENHU, a leading global bioprinting company, today announced the launch of the R-GEN platform and SHAPER, a new bioprinter and software designed to cover the entire biofabrication process.

From regenHU Ltd. 4 Nov 2020

Researchers investigate the effect of palm oil extract on mice liver cells

Palm oil contains abundant quantities of vitamin E compounds, which include tocopherols and tocotrienols.These compounds have anti-oxidant effects, which protect cells from damage from toxic chemical produced by metabolic processes.

4 Nov 2020

CCA is urged to examine challenges specific to approval and use of gene therapies

Gene therapies are being approved for use in Canada, but could strain healthcare budgets and exacerbate existing treatment inequities across the country.

4 Nov 2020

Study sheds light on possible lung damage caused by COVID-19 virus

The study, published today in The Lancet's eBioMedicine, by King's College London in collaboration with University of Trieste and the International Centre for Genetic Engineering and Biology in Italy, shows the unique characteristics to the SARS-CoV-2 virus and may explain why patients suffer from 'long COVID'.

4 Nov 2020

Most SARS-CoV-2-infected individuals develop durable B cell-mediated immunity

Researchers from the Johns Hopkins University and The Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA, investigated the durability of B cell immunity following SARS-CoV-2 infection and recovery in their recent work published on the preprint server medRxiv.

3 Nov 2020

Evidence of robust and persistent antibodies against SARS-CoV-2

A team of researchers from the Icahn School of Medicine at Mount Sinai, New York, have worked in collaboration to try and answer one of the most baffling questions surrounding the coronavirus disease 19 (COVID-19) pandemic: do antibodies against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) last after a primary infection?

3 Nov 2020

SARS-CoV-2 T-cell immunity is retained for at least six months

Now, a new study published on the preprint server bioRxiv shows that functional SARS-CoV-2-specific T-cell responses are retained for six months following infection. However, the strength of this response depends on the clinical features of the primary infection.

3 Nov 2020

Study finds a subset of quick COVID-19 healers and antibody 'sustainers'

One of the pressing questions about COVID-19 remains: How long does immunity last? One key indicator of immunity is the presence of virus-specific antibodies.

3 Nov 2020

AI speech processing framework detects inaudible COVID-19 cough

Now, a team of researchers at the Massachusetts Institute of Technology (MIT) has found that asymptomatic people may differ from those who are healthy in the way they cough. The differences are inaudible to the human ear but can be detected by artificial intelligence (AI).

3 Nov 2020

Some of the main osteoporosis treatments could have a protective effect against COVID-19

Some of the principal treatments for osteoporosis, denosumab, zoledronate and calcium, could have a protective effect against COVID-19 in patients who take them, specifically a 30 to 40% reduction in the rate of infection, according to the results of a joint study by Hospital del Mar, the Hospital del Mar Medical Research Institute (IMIM), Pompeu Fabra University and the Pere Virgili Health Park.

3 Nov 2020

Rapid generation of divergent synthetic antibodies against SARS-CoV-2 in a cell-free engineering platform

In a groundbreaking bioRxiv paper, a research group from the Massachusetts Institute of Technology (MIT), Harvard University and Howard Hughes Medical Institute in the US engineered antibodies against the receptor-binding domain (RBD) of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike glycoprotein by using a novel approach. In doing so, they also identified more than 800 predicted binder families.

3 Nov 2020

Primary care for acute health conditions declined dramatically since UK lockdown

Researchers have conducted a study showing substantial reductions in the number of people attending primary care services for key physical and mental health conditions in the UK since lockdown was introduced on March 23rd this year.

3 Nov 2020

Eye's cornea can resist infection from novel coronavirus

New findings from researchers at Washington University School of Medicine in St. Louis suggest the eye's cornea can resist infection from the novel coronavirus.

3 Nov 2020